Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Fritsche

Showing results (101-110 of 214) with videos related to

Pageof 22
Sort By:
The Journal of Antimicrobial Chemotherapy|December 6, 2005
Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nationsRonald N Jones, James E Ross, Thomas R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|April 6, 2007
Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniaeRonald N Jones, Helio S Sader, Matthew G Stilwell, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|January 18, 2007
Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004)Lalitagauri M Deshpande, Ronald N Jones, Thomas R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|November 13, 2007
Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenemRonald N Jones, Helio S Sader, Thomas R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|March 24, 2009
Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007)Thomas R Fritsche, Helio S Sader, Matthew G Stillwell, et al.
Diagnostic Microbiology and Infectious Disease|October 9, 2007
WITHDRAWN: Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenemRonald N Jones, Helio S Sader, Thomas R Fritsche, et al.
The Journal of Experimental Medicine|January 11, 1991
Human platelet-mediated cytotoxicity against Toxoplasma gondii: role of thromboxaneE C Yong, E Y Chi, T R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|November 16, 2004
Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwideHelio S Sader, Jennifer M Streit, Thomas R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|May 3, 2006
Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004)Michael A Pfaller, Helio S Sader, Thomas R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|April 25, 2006
Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA)Paul R Rhomberg, Thomas R Fritsche, Helio S Sader, et al.
Pageof 22

Showing results (101-110 of 214) with videos related to

Sort By:
Pageof 22
The Journal of Antimicrobial Chemotherapy|December 6, 2005
Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nationsRonald N Jones, James E Ross, Thomas R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|April 6, 2007
Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniaeRonald N Jones, Helio S Sader, Matthew G Stilwell, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|January 18, 2007
Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004)Lalitagauri M Deshpande, Ronald N Jones, Thomas R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|November 13, 2007
Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenemRonald N Jones, Helio S Sader, Thomas R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|March 24, 2009
Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007)Thomas R Fritsche, Helio S Sader, Matthew G Stillwell, et al.
Diagnostic Microbiology and Infectious Disease|October 9, 2007
WITHDRAWN: Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenemRonald N Jones, Helio S Sader, Thomas R Fritsche, et al.
The Journal of Experimental Medicine|January 11, 1991
Human platelet-mediated cytotoxicity against Toxoplasma gondii: role of thromboxaneE C Yong, E Y Chi, T R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|November 16, 2004
Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwideHelio S Sader, Jennifer M Streit, Thomas R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|May 3, 2006
Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004)Michael A Pfaller, Helio S Sader, Thomas R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|April 25, 2006
Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA)Paul R Rhomberg, Thomas R Fritsche, Helio S Sader, et al.
Pageof 22